How we manage adults with myelodysplastic syndrome
Citations
32 citations
28 citations
Cites background from "How we manage adults with myelodysp..."
...Moreover, standard induction chemotherapy could usually be suggested as a bridge to transplant cytoreduction for patients with favorable or intermediate risk karyotype, whereas HMA may be preferred for cases showing unfavorable genetic lesions [89,100]....
[...]
24 citations
17 citations
11 citations
References
4,133 citations
2,310 citations
2,282 citations
"How we manage adults with myelodysp..." refers background in this paper
...In a randomised phase 3 clinical trial in higher-risk MDS patients, a survival benefit with azacitidine was demonstrated over conventional care regimens (Fenaux et al, 2009), with a median survival of 24 4 months compared to 15 months....
[...]
...Hypomethylating agents, including azacitidine (and decitabine, not approved in Europe)—are currently the first line treatment in most cases of higher-risk MDS (Fenaux et al, 2009; Kantarjian et al, 2012)....
[...]
...The survival advantage with azacitidine was seen irrespective of age, marrow blast percentage and karyotype (Fenaux et al, 2009)....
[...]
...The role of intensive chemotherapy (IC, mainly based on anthracycline-cytarabine combinations) in HR-MDS has been challenged by the advent of HMAs (Fenaux et al, 2009): IC can induce 40–60% complete response (CR) rates but these are usually of short duration (median less than 12 months) (Wattel et…...
[...]
1,485 citations